
Tempest Therapeutics fell 93.5% from $4.75 to $0.31, behind the S&P 500's +10.2%. Its worst day was Sep 17 (−26.0%), and its low came Nov 18 at $0.31.
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Tempest Therapeutics shares fell 23.3%, while the S&P 500 rose 0.9%.
−23.3% · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
EPS of $-0.62 beat the $-0.62 estimate on $0.00 revenue.
−12.1% · S&P 500 −0.3%
Tempest Therapeutics shares rose 29.7%, while the S&P 500 fell 0.1%.
+29.7% · S&P 500 −0.1%
EPS of $-0.50 missed the $-0.28 estimate on $0.00 revenue.
−12.4% · S&P 500 −1.2%
EPS of $-0.34 missed the $-0.30 estimate on $0.00 revenue.
−13.2% · S&P 500 −0.2%
Tempest Therapeutics shares rose 60.2%, while the S&P 500 fell 0.4%.
+60.2%, the year's best day, on 105M shares, the year's heaviest volume · S&P 500 −0.4%
Tempest Therapeutics shares fell 18.6%, while the S&P 500 fell 4.4%.
−18.6% · S&P 500 −4.4%
EPS of $-0.21 beat the $-0.32 estimate on $0.00 revenue.
−10.4% · S&P 500 −1.9%
Where it ended: a close of $0.31 on Nov 18, 2026.
Nothing in the past 12 months.
All TPST dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TPST and SPY from Benzinga historical bars. Not investment advice.